Phase II trial to evaluate immune-related biomarkers for pathological response in stage II-III HER2-positive breast cancer receiving neoadjuvant chemotherapy with subsequent randomization to multi-epitope HER2 vaccine versus placebo in patients with residual disease post-neoadjuvant chemotherapy.
Abstract
TPS610
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 01, 2022
- Source ID
- 10.1200/jco.2022.40.16_suppl.tps610
Entities
People
- Alvaro Moreno-aspitia
- Brenda Ernst
- David W. Hillman
- Donald W. Northfelt
- Kathryn Jean Ruddy
- Keith L Knutson
- Kostandinos Sideras
- Matthew P Goetz
- Nadine Norton
- Pooja Prem Advani
- Sarah Bruggeman
- Saranya Chumsri
Organizations
- Erasmus University Rotterdam
- Mayo Clinic
- United States Department of Defense